SGMO Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own SGMO shares is 124, representing 24.64% of the company's common stock.

TWO SIGMA INVESTMENTS, LP, in the last quarter, reduced its stake in SGMO by -74.48% restricting it's holding to 554.86 thousand shares of worth nearly $371.86K. DIMENSIONAL FUND ADVISORS LP also lessened -3.86% of the SGMO shares from its portfolio, reducing its holding to 552.88 thousand shares of worth $370.54K. MORGAN STANLEY also shunned SGMO shares holding by -41.25% last quarter which brought its holding to 534.07 thousand shares worth $357.93K.

As per its latest 13F filing, MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. increased its stake in SGMO by 100% in the last quarter. The institutional holder raised its holding to 493.43 thousand shares having worth more than $838.83K. SCHONFELD STRATEGIC ADVISORS LLC also added 100% more shares of SGMO to its portfolio, raising its holding to 445.3 thousand shares of worth $298.44K. FMR LLC also increased its SGMO shares holding by 40.16% which brought its holding to 436.66 thousand shares worth $292.65K.

The insider with the most stakes in SGMO is Biogen MA Inc. , at the company. Additionally, SGMO stock is highly held by 10 percent owner BIOGEN INC. and President & CEO LANPHIER EDWARD O II among others.

Company executives, directors, and other insiders own 2.38% percent of Sangamo Therapeutics, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which SGMO insiders have sold stock, totaling 0 shares. Insiders that have sold shares include BIOGEN INC., BIOGEN MA INC., and LOEB GARY.

There have been 0 transaction(s) during the past 6-months in which Sangamo Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 0 Sangamo Therapeutics, Inc. shares are held by insiders, which represents about 2.38% of SGMO stock.

SGMO , Biogen MA Inc. holds the largest portfolio of the company's shares. SGMO shares owned by Biogen total nearly 23.65 million.

TWO SIGMA INVESTMENTS, LP is the largest institutional owner in SGMO which holds 554.86 thousand shares worth $371.86K or 0.31% of the total SGMO shares outstanding followed by DIMENSIONAL FUND ADVISORS LP with ownership of 552.88 thousand shares representing 0.31% of the SGMO ownership. MORGAN STANLEY is the third largest stakeholder with 534.07 thousand shares or 0.3% of the ownership worth more than $357.93K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the SGMO is concerned, it is a stock which is optionable.

Number of SGMO shares short is 22.45M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 208.65M shares of SGMO are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, SGMO has 189.70M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for SGMO is 1.97.